Virax Biolabs Reports Positive Early Pilot Data for Long COVID Test, Plans US Market Entry
VRAX has more than doubled off its 52-week low of $0.1.
Summary
Virax Biolabs reported positive early clinical data for its ViraxImmune™ test for Long COVID, demonstrating strong performance metrics and outlining a strategy for U.S. market entry.
Key Events · Product Development and Regulatory · VRAX
-
Positive Pilot Data for ViraxImmune™
The blood-based test for Long COVID and related syndromes achieved 88% specificity and 92% positive predictive value in early pilot data, demonstrating measurable separation between PAIS patients and healthy controls.
-
Significant Market Opportunity
The company estimates up to 21 million adults in the U.S. may be living with Long COVID/PAIS, representing a substantial potential U.S. testing opportunity in an area with unmet diagnostic needs.
-
Path to U.S. Market Entry
Virax plans to pursue an initial U.S. Laboratory Developed Test (LDT) route for PAIS, with broader in vitro diagnostic (IVD) development planned over time.
-
Next Clinical Validation Milestone
A larger clinical validation analysis involving 300 additional participants is expected to begin in Q4 2026, with results anticipated in Q1 2027.
Analysis · VRAX · Life Sciences
Virax Biolabs announced encouraging early pilot data for its ViraxImmune™ blood test for Long COVID and related post-acute infection syndromes. The test showed strong specificity and positive predictive value, supporting its potential in a large, underserved market. This positive development is critical for the micro-cap company as it outlines a clear path toward larger clinical validation and a U.S. market entry strategy via a Laboratory Developed Test (LDT) route.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VRAX was trading at $0.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.10 to $1.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.